Amphastar Q1 revenues $140M (+16% YoY); GAAP EPS $0.50, adj. EPS $0.62

Amphastar Pharmaceuticals, Inc.

2023-Q1 EPS reported $0.50 revenue$140,022,000

Net revenues $140.0M vs $120.4M YoY; GAAP net income $26.0M ($0.50 diluted EPS).
Adjusted non-GAAP net income $32.1M ($0.62 diluted EPS), up from $24.6M ($0.47) YoY.
Key growth drivers: glucagon, Primatene MIST, epinephrine; new launches include regadenoson and intranasal naloxone.
Proposed BAQSIMI acquisition noted as transformative for diabetes portfolio and branded product strategy.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: revenue 140.0 million, net income 26.0 million, EPS 0.50.

Period: three months ended March 31, 2023
Revenue: 140.0 million
Net income: 26.0 million
EPS: 0.50
Result: reported results

Exact text from the filing

Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

Amphastar Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001297184-23-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.